Loading
Trying to reduce toxicity by swapping cisplatin for cetuximab during radiotherapy in HPV-positive oropharyngeal cancer backfired: cetuximab gave worse survival and more recurrences with no reduction in toxicity, so cisplatin remains standard.
Phase 3 non-inferiority trial of 849 patients with HPV-positive (p16-positive) oropharyngeal cancer randomised to accelerated intensity-modulated radiotherapy with cisplatin or with cetuximab.
Five-year overall survival was 77.9 percent with cetuximab against 84.6 percent with cisplatin (hazard ratio 1.45, non-inferiority not met) and five-year locoregional failure 17.3 versus 9.9 percent; acute and late toxicity rates were similar.
Cisplatin chemoradiation is the standard for HPV-positive oropharyngeal cancer; cetuximab is reserved for patients who cannot receive cisplatin.
Shares HPV-positive oropharyngeal cancer, Oropharyngeal cancer (tonsil and base of tongue), Cetuximab, The Lancet.
Shares HPV-positive oropharyngeal cancer, Oropharyngeal cancer (tonsil and base of tongue), Cetuximab, Cisplatin.
Shares HPV-positive oropharyngeal cancer, Oropharyngeal cancer (tonsil and base of tongue), Cisplatin.
Shares HPV-positive oropharyngeal cancer, Oropharyngeal cancer (tonsil and base of tongue).
Shares HPV-positive oropharyngeal cancer, Oropharyngeal cancer (tonsil and base of tongue).
Shares HPV-positive oropharyngeal cancer, Oropharyngeal cancer (tonsil and base of tongue), Cisplatin.
Shares HPV-positive oropharyngeal cancer, Oropharyngeal cancer (tonsil and base of tongue), Cisplatin.
Shares The Lancet, Cisplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/